Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.

Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, Shochat C, Cazzaniga G, Biondi A, Basso G, Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Mann G, Binder V, Borkhardt A, Kempski H, Trka J, Bielorei B, Avigad S, Stark B, Smith O, Dastugue N, Bourquin JP, Tal NB, Green AR, Izraeli S.

Lancet. 2008 Oct 25;372(9648):1484-92. doi: 10.1016/S0140-6736(08)61341-0. Epub 2008 Sep 19.

PMID:
18805579
2.

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.

Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, Bateman CM, Anderson K, Chaplin T, Young BD, Harrison CJ, Kempski H, So CW, Ford AM, Greaves M.

Blood. 2009 Jan 15;113(3):646-8. doi: 10.1182/blood-2008-08-170928. Epub 2008 Oct 16.

3.

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.

Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K, Macintyre EA, Villeval JL, Vainchenker W, Berger R, Bernard OA, Delabesse E, Penard-Lacronique V.

Blood. 2007 Mar 1;109(5):2202-4. Epub 2006 Oct 26.

4.

Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.

Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S, Plon SE, Basso G, Pession A, Rabin KR.

Br J Haematol. 2009 Mar;144(6):930-2. doi: 10.1111/j.1365-2141.2008.07552.x. Epub 2008 Dec 20.

5.

Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.

Groet J, McElwaine S, Spinelli M, Rinaldi A, Burtscher I, Mulligan C, Mensah A, Cavani S, Dagna-Bricarelli F, Basso G, Cotter FE, Nizetic D.

Lancet. 2003 May 10;361(9369):1617-20.

PMID:
12747884
6.

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.

Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S.

Blood. 2010 Feb 4;115(5):1006-17. doi: 10.1182/blood-2009-08-235408. Epub 2009 Nov 24.

7.

Prognosis of Down's syndrome with acute leukaemia.

Levitt GA, Stiller CA, Chessells JM.

Arch Dis Child. 1990 Feb;65(2):212-6.

8.

[GATA1 analysis in myeloproliferative disorders associated to trisomy 21].

Fuster Soler JL, Norton A, Galera Miñarro A, Bermúdez Cortés M, Llinares Riestra ME, Ortuño Giner F.

An Pediatr (Barc). 2011 Jan;74(1):31-7. doi: 10.1016/j.anpedi.2010.08.012. Epub 2010 Sep 25. Spanish.

9.

Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.

Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JP, Beverloo HB, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Russell LJ, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, den Boer ML, Zwaan CM.

Leukemia. 2012 Oct;26(10):2204-11. doi: 10.1038/leu.2012.84. Epub 2012 Mar 22.

PMID:
22441210
10.

JAK2--a new player in acute lymphoblastic leukaemia.

Mullighan CG.

Lancet. 2008 Oct 25;372(9648):1448-50. doi: 10.1016/S0140-6736(08)61342-2. Epub 2008 Sep 19. No abstract available.

PMID:
18805580
11.

Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Hasle H, Clemmensen IH, Mikkelsen M.

Lancet. 2000 Jan 15;355(9199):165-9.

PMID:
10675114
12.

A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21.

Tigay JH.

J Pediatr Oncol Nurs. 2009 Nov-Dec;26(6):362-8. doi: 10.1177/1043454209340321. Review.

PMID:
20032297
13.

Mutation characterization in the GATA-1 gene in patients with Down's Syndrome diagnosed with transient abnormal myelopoiesis or acute megakaryoblastic leukemia.

Mansini AP, Rubio PL, Rossi JG, Gallego MS, Medina A, Zubizarreta PA, Felice MS, Alonso CN.

Arch Argent Pediatr. 2013 Dec;111(6):532-6. doi: 10.1590/S0325-00752013000600013. English, Spanish.

14.

Haematopoietic development and leukaemia in Down syndrome.

Roberts I, Izraeli S.

Br J Haematol. 2014 Dec;167(5):587-99. doi: 10.1111/bjh.13096. Epub 2014 Aug 22. Review.

PMID:
25155832
15.

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, Willman CL, Mikhail FM, Meyer J, Carroll AJ, Williams RT, Cheng J, Heerema NA, Basso G, Pession A, Pui CH, Raimondi SC, Hunger SP, Downing JR, Carroll WL, Rabin KR.

Nat Genet. 2009 Nov;41(11):1243-6. doi: 10.1038/ng.469. Epub 2009 Oct 18.

16.

[Research advances in the role of JAK2 mutations in acute leukemia].

Zhang HY, Zhai XW.

Zhongguo Dang Dai Er Ke Za Zhi. 2015 Jun;17(6):644-9. Review. Chinese.

17.

JAK/STAT signaling in hematological malignancies.

Vainchenker W, Constantinescu SN.

Oncogene. 2013 May 23;32(21):2601-13. doi: 10.1038/onc.2012.347. Epub 2012 Aug 6. Review.

PMID:
22869151
18.

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.

Hornakova T, Springuel L, Devreux J, Dusa A, Constantinescu SN, Knoops L, Renauld JC.

Haematologica. 2011 Jun;96(6):845-53. doi: 10.3324/haematol.2010.036350. Epub 2011 Mar 10.

19.

The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.

Li F, Guo HY, Wang M, Geng HL, Bian MR, Cao J, Chen C, Zeng LY, Wang XY, Wu QY.

Int J Biol Macromol. 2013 Sep;60:186-95. doi: 10.1016/j.ijbiomac.2013.05.029. Epub 2013 Jun 5.

PMID:
23748007
20.

Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.

Nikolaev SI, Garieri M, Santoni F, Falconnet E, Ribaux P, Guipponi M, Murray A, Groet J, Giarin E, Basso G, Nizetic D, Antonarakis SE.

Nat Commun. 2014 Aug 8;5:4654. doi: 10.1038/ncomms5654.

Items per page

Supplemental Content

Write to the Help Desk